<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->
### Database Entries (Oct 29)
Chen P, Nirula A, et int., and Skovronsky DM. [‚ÄúSARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.‚Äù](/search/?article=Chen20l) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2029849](https://doi.org/10.1056/nejmoa2029849). \[[PubMed33113295](https://www.ncbi.nlm.nih.gov/pubmed/33113295/)\]


### [Press Release (Oct 07)](/page/updates/#press.release)

[Lilly Statement Regarding NIH‚Äôs ACTIV-3 Clinical Trial](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly20201027.pdf)

### Database Entries (Oct 26)
Pan H, Peto R, et int., and Swaminathan S. [‚ÄúRepurposed antiviral drugs for COVID-19 ‚Äìinterim WHO SOLIDARITY trial results.‚Äù](/search/?article=Pan20b) _medRxiv_, 2020. [doi.org/10.1101/2020.10.15.20209817](https://doi.org/10.1101/2020.10.15.20209817).
### Database Entries (Oct 26)
Rocco PRM, Silva PL, et int., and Lapa e Silva JR. [‚ÄúEarly use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial.‚Äù](/search/?article=Rocco20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.21.20217208](https://doi.org/10.1101/2020.10.21.20217208).

### [Clinical Trials (Oct 22)](/page/updates/#clinical.trials)
[16 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-22)
### Database Entries (Oct 22)
Rosenke K, Leventhal S, et int., and Stein DA. [‚ÄúInhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino-oligomers.‚Äù](/search/?article=Rosenke20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.29.319731](https://doi.org/10.1101/2020.09.29.319731). \[[PubMed33024974](https://www.ncbi.nlm.nih.gov/pubmed/33024974/)\] \[[PMC7536879](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536879/)\]
### Database Entries (Oct 22)
Yin W, Luan X, et int., and Xu HE. [‚ÄúStructural basis for repurposing a 100-years-old drug suramin for treating COVID-19.‚Äù](/search/?article=yin20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.06.328336](https://doi.org/10.1101/2020.10.06.328336).

### [Press Release (Oct 16)](/page/updates/#press.release)
- [IFN Lambda EigerBioPharmaceuticals](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Eiger20201017.pdf)

### [Clinical Trials (Oct 15)](/page/updates/#clinical.trials)
[5 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-15)


### Database Entries (Oct 13)
Olaleye OA, Kaur M, and Onyenaka CC. [‚ÄúAmbroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein‚Äôs Receptor Binding Domain and Recombinant Human ACE2.‚Äù](/search/?article=Olaleye20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.13.295691](https://doi.org/10.1101/2020.09.13.295691). \[[PubMed32995775](https://www.ncbi.nlm.nih.gov/pubmed/32995775/)\] \[[PMC7523101](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523101/)\]

### Database Entries (Oct 13)
Kaptein SJF, Jacobs S, et int., and Delang L. [‚ÄúFavipiravir at high doses has potent antiviral activity in SARS-CoV-2‚àíinfected hamsters, whereas hydroxychloroquine lacks activity.‚Äù](/search/?article=Kaptein20) _Proceedings of the National Academy of Sciences_, 2020. [doi.org/10.1073/pnas.2014441117](https://doi.org/10.1073/pnas.2014441117). \[[PubMed33037151](https://www.ncbi.nlm.nih.gov/pubmed/33037151/)\]

### Database Entries (Oct 12)
Arabi YM, Asiri AY, et int., and Alothman A. [‚ÄúInterferon Beta-1b and Lopinavir‚ÄìRitonavir for Middle East Respiratory Syndrome.‚Äù](/search/?article=Arabi20) _NEJM_, 2020. [doi.org/10.1056/nejmoa2015294](https://doi.org/10.1056/nejmoa2015294). \[[PubMed33026741](https://www.ncbi.nlm.nih.gov/pubmed/33026741/)\]
### Database Entries (Oct 12)
Beigel JH, Tomashek KM, et int., and Lane HC. [‚ÄúRemdesivir for the Treatment of Covid-19 ‚Äî Final Report.‚Äù](/search/?article=Beigel20) _NEJM_, 2020. [doi.org/10.1056/nejmoa2007764](https://doi.org/10.1056/nejmoa2007764). \[[PubMed32445440](https://www.ncbi.nlm.nih.gov/pubmed/32445440/)\] \[[PMC7262788](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/)\]
### Database Entries (Oct 12)
Cho J, Lee YJ, et int., and Choi J. [‚ÄúAntiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19.‚Äù](/search/?article=Cho20) _SREP_, 2020. [doi.org/10.1038/s41598-020-72879-7](https://doi.org/10.1038/s41598-020-72879-7). \[[PubMed33004837](https://www.ncbi.nlm.nih.gov/pubmed/33004837/)\] \[[PMC7530981](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530981/)\]
### Database Entries (Oct 12)
Gilmore K, Zhou Y, et int., and Seeberger PH. [‚ÄúIn vitro efficacy of Artemisinin-based treatments against SARS-CoV-2.‚Äù](/search/?article=Gilmore20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.05.326637](https://doi.org/10.1101/2020.10.05.326637).
### [Preprints => Peer-Reviewed Publications (Oct 12)](/page/updates/#preprints.peer-reviewed.publications)

3 published preprints were added.

### [Clinical Trials (Oct 09)](/page/updates/#clinical.trials)
[23 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-08)


### [New spike structures (Oct 08)](/page/spike-structures/#fig11)
Figure 11. Phylogenetic tree, multiple sequence alignment, and sequence variability of the SARS-related coronavirus (SARSr-CoV) spike receptor binding domain (RBD).

### [New spike structures (Oct 08)](/page/spike-structures/#fig12)
Figure 12. Phylogenetic tree, multiple sequence alignment, and sequence variability of the SARS-related coronavirus (SARSr-CoV) trimeric spike.

### Webinar (Oct 07)
Monoclonal Antibodies for the Prevention and Treatment of COVID 19. [video](https://www.youtube.com/watch?v=YUj9jBlTCrY)

### [Press Release (Oct 07)](/page/updates/#press.release)
- [Lilly SARS-CoV-2 Neutralizing Antibody Slides Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly202010071.pdf)
- [Lilly update on SARS-CoV-2 neutralizing antibody programs Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly202010072.pdf)

### Database Entries (Oct 05)
Ansarin K, Tolouian R, et int., and Chapman KR. [‚ÄúEffect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial.‚Äù](/search/?article=Ansarin20) _BioImpacts_, 2020. [doi.org/10.34172/bi.2020.27](https://doi.org/10.34172/bi.2020.27). \[[PubMed32983936](https://www.ncbi.nlm.nih.gov/pubmed/32983936/)\] \[[PMC7502909]\](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502909/)
### Database Entries (Oct 05)
Wahl A, Gralinski L, et int., and Garcia JV. [‚ÄúAcute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801.‚Äù](/search/?article=Wahl20) _Research square_, [2020. doi.org/10.21203/rs.3.rs-80404/v1](https://doi.org/10.21203/rs.3.rs-80404/v1). \[[PubMed32995766](https://www.ncbi.nlm.nih.gov/pubmed/32995766/)\] \[[PMC7523135](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523135/)\]
### Database Entries (Oct 03)
Jones BE, Brown-Augsburger PL, et int., and Falconer E. [‚ÄúLY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.‚Äù](/search/?article=Jones20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.30.318972](https://doi.org/10.1101/2020.09.30.318972).
### Database Entries (Oct 03)
Sagar S, Rathinavel AK, et int., and Radhakrishnan P. [‚ÄúBromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells.‚Äù](/search/?article=Sagar20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.16.297366](https://doi.org/10.1101/2020.09.16.297366). \[[PubMed32995771](https://www.ncbi.nlm.nih.gov/pubmed/32995771/)\] \[[PMC7523097](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523097/)\]
### Database Entries (Oct 03)
Watson A, Ferreira L, et int., and Stroud R. [‚ÄúPeptide Antidotes to SARS-CoV-2 (COVID-19).‚Äù](/search/?article=Watson20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.06.238915](https://doi.org/10.1101/2020.08.06.238915).

### [Press Release (Oct 02)](/page/updates/#press.release)

[Synairgen plc, Interim results for the six months ended 30 June 2020](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Synairgen20200930.pdf)

### [Press Release (Oct 02)](/page/updates/#press.release)

[Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19outpatient setting](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly20200930.pdf)

### [Press Release (Oct 02)](/page/updates/#press.release)

[Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms inNon-Hospitalized COVID-19 Patients](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20200930.pdf)

### [Clinical Trials (Oct 01)](/page/updates/#clinical.trials)
[9 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-01)

### Database entries (Oct 01)
Proud PC, Tsitoura D, et int., and Carroll MW. [‚ÄúProphylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.‚Äù](/search/?article=Proud20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.309914](https://doi.org/10.1101/2020.09.25.309914).
### Database entries (Oct 01)
Son J, Huang S, et int., and Ding S. [‚ÄúNitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model.‚Äù](/search/?article=Son20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.24.312165](https://doi.org/10.1101/2020.09.24.312165).
### Database entries (Oct 01)
Fagre AC, Manhard J, et int., and Schountz T. [‚ÄúA potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters.‚Äù](/search/?article=Fagre20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.313601](https://doi.org/10.1101/2020.09.25.313601).
### Database entries (Oct 01)
Lin C, Li Y, et int., and Chen J. [‚ÄúCeftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction.‚Äù](/search/?article=Lin20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.14.295956](https://doi.org/10.1101/2020.09.14.295956).
### Database entries (Oct 01)
Xiao T, Lu J, et int., and Chen B. [‚ÄúA trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro.‚Äù](/search/?article=Xiao20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.18.301952](https://doi.org/10.1101/2020.09.18.301952). \[[PubMed32995768](https://www.ncbi.nlm.nih.gov/pubmed/32995768/)\] \[[PMC7523094](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523094/)\]
### Database entries (Oct 01)
Zhang L, Cao L, et int., and Zhu F. [‚ÄúA proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.‚Äù](/search/?article=Zhang20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.23.309294](https://doi.org/10.1101/2020.09.23.309294).
### Database entries (Sep 29)
Brunaugh AD, Seo H, et int., and Smyth HD. [‚ÄúBroad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models.‚Äù](/search/?article=Brunaugh20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.09.24.310490](https://doi.org/10.1101/2020.09.24.310490).
### Database entries (Sep 29)
Curreli F, Victor SMB, et int., and Debnath AK. [‚ÄúStapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro.‚Äù](/search/?article=Curreli20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.25.266437](https://doi.org/10.1101/2020.08.25.266437).
